A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 10 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Abiraterone, specifically in the 500mg strength and 90 tablet pack size. Under § 130a Abs. 8 SGB V, health insurance funds and pharmaceutical companies can enter into framework di
The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process will provide uniform contract conditions and access procedu
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves establishing non-exclusive discount agreements for the medication Certolizumab pegol, as per § 130a Abs. 8 SGB V. The agreements will be made under an Open-House model, allowing all interested pharmaceutical companies to participate during the application period, p
This contract opportunity involves establishing non-exclusive discount agreements for pharmaceuticals containing the active ingredients Brinzolamid and Brimonidin (official ATC code: S01EC24) under the German Social Code. The agreements will be made through an Open-House model, allowing all interest
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e
The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac
This is not a standard procurement process but an open-house model for pharmaceutical companies. The AOK Bayern intends to establish non-exclusive discount agreements for the drug Leuprorelin (ATC L02AE02) with all interested pharmaceutical companies that meet the specified eligibility criteria. The
This announcement is for establishing agreements with pharmaceutical companies as per § 130a Abs. 8 Sentence 1 SGB V. The invitation to participate is directed only to pharmaceutical entrepreneurs or associations of pharmaceutical entrepreneurs as defined in § 4 Abs. 18 of the Medicines Act. This is
This announcement is for establishing agreements with companies or consortia of companies for blood glucose test strips in accordance with § 130a Abs. 8 Satz 1 of the Fifth Book of the Social Code (SGBV) for the state of North Rhine-Westphalia. The agreements will include discount contracts, allowin
